TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cogstate Ltd ( (AU:CGS) ) just unveiled an announcement.
Cogstate Ltd reported a record-breaking fiscal year 2025, with revenue reaching $53.1 million, a 22% increase, and a net profit before tax of $13.9 million, reflecting nearly 100% growth. The company’s core business in clinical trials generated $50.6 million in revenue, marking a 28% increase, and new contract sales surged by 53% to $41.3 million. The company’s operational rigor and market leadership contributed to a significant expansion in earnings leverage, with EBITDA and EBIT margins rising to 30% and 25%, respectively. These results underscore Cogstate’s strategic progress and growing momentum, positioning the company strongly for the future.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is a neuroscience technology company focused on optimizing brain health assessments to advance new medicine development and enable earlier clinical insights in healthcare. The company provides computerized cognitive tests and supports electronic clinical outcome assessment solutions, aiming to replace paper assessments with real-time data capture. Cogstate has been supporting biopharmaceutical companies, academic institutions, and clinical care needs globally for over 20 years, with a focus on digital measures of cognition for primary care physicians and consumers.
Average Trading Volume: 181,386
Technical Sentiment Signal: Buy
Current Market Cap: A$410.9M
For an in-depth examination of CGS stock, go to TipRanks’ Overview page.